l-asparaginase Injection 750 IU/ml

The company, established in 2016 and later restructured as a private limited entity in 2018, specializes in manufacturing APIs, advanced intermediates, and finished dosage forms. With robust relationships in the pharmaceutical industry, it has built a strong customer base of over 50 clients and achieved an annual turnover exceeding 200 crore. The company operates extensive facilities capable of scaling from lab-scale development to bulk production, supporting its global expansion strategy. Committed to ethical practices and social responsibility, the company aims to make healthcare affordable and accessible worldwide, with export markets across Asia, Latin America, and Africa.